Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …

In recent years, many therapeutic advances have been made in the management of
castration-resistant prostate cancer, with the development and approval of many new drugs …

Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling
continues to be the mainstay treatment of advanced-stage prostate cancer. The use of …

Context Various molecular mechanisms play a role in the development of resistance to
androgen deprivation therapy in castration-resistant prostate cancer (CRPC). Objective To …

In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …

Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR)
signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal …

After initial response to androgen receptor (AR) targeting drugs abiraterone or
enzalutamide, most patients develop progressive disease and therefore, castration resistant …

The androgen signaling axis has been the main therapeutic target in the management of
advanced prostate cancer for several decades. Over the past years, significant advances …

The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical
landscape of prostate cancer treatment. Both drugs were designed to further suppress …

The new-generation hormonal agent enzalutamide has been approved for the treatment of
metastatic castration-resistant prostate cancer (CRPC), in both post-and predocetaxel …